Overview

Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of BAT2022 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bio-Thera Solutions
Treatments:
Antibodies, Blocking